Clinical utility of antifungal susceptibility testing

Invasive fungal diseases cause significant morbidity and mortality, in particular affecting immunocompromised patients. Resistant organisms are of increasing importance, yet there are many notable differences in the ability to both perform and interpret antifungal susceptibility testing compared wit...

Descripción completa

Detalles Bibliográficos
Autores principales: McCarty, Todd P, Luethy, Paul M, Baddley, John W, Pappas, Peter G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9237445/
https://www.ncbi.nlm.nih.gov/pubmed/35774069
http://dx.doi.org/10.1093/jacamr/dlac067
_version_ 1784736793341460480
author McCarty, Todd P
Luethy, Paul M
Baddley, John W
Pappas, Peter G
author_facet McCarty, Todd P
Luethy, Paul M
Baddley, John W
Pappas, Peter G
author_sort McCarty, Todd P
collection PubMed
description Invasive fungal diseases cause significant morbidity and mortality, in particular affecting immunocompromised patients. Resistant organisms are of increasing importance, yet there are many notable differences in the ability to both perform and interpret antifungal susceptibility testing compared with bacteria. In this review, we will highlight the strengths and limitations of resistance data of pathogenic yeasts and moulds that may be used to guide treatment and predict clinical outcomes.
format Online
Article
Text
id pubmed-9237445
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-92374452022-06-29 Clinical utility of antifungal susceptibility testing McCarty, Todd P Luethy, Paul M Baddley, John W Pappas, Peter G JAC Antimicrob Resist Review Invasive fungal diseases cause significant morbidity and mortality, in particular affecting immunocompromised patients. Resistant organisms are of increasing importance, yet there are many notable differences in the ability to both perform and interpret antifungal susceptibility testing compared with bacteria. In this review, we will highlight the strengths and limitations of resistance data of pathogenic yeasts and moulds that may be used to guide treatment and predict clinical outcomes. Oxford University Press 2022-06-28 /pmc/articles/PMC9237445/ /pubmed/35774069 http://dx.doi.org/10.1093/jacamr/dlac067 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Review
McCarty, Todd P
Luethy, Paul M
Baddley, John W
Pappas, Peter G
Clinical utility of antifungal susceptibility testing
title Clinical utility of antifungal susceptibility testing
title_full Clinical utility of antifungal susceptibility testing
title_fullStr Clinical utility of antifungal susceptibility testing
title_full_unstemmed Clinical utility of antifungal susceptibility testing
title_short Clinical utility of antifungal susceptibility testing
title_sort clinical utility of antifungal susceptibility testing
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9237445/
https://www.ncbi.nlm.nih.gov/pubmed/35774069
http://dx.doi.org/10.1093/jacamr/dlac067
work_keys_str_mv AT mccartytoddp clinicalutilityofantifungalsusceptibilitytesting
AT luethypaulm clinicalutilityofantifungalsusceptibilitytesting
AT baddleyjohnw clinicalutilityofantifungalsusceptibilitytesting
AT pappaspeterg clinicalutilityofantifungalsusceptibilitytesting

Ejemplares similares